{"DataElement":{"publicId":"5042476","version":"1","preferredName":"Compound Clinical Trial Phase Type","preferredDefinition":"Text term that represents the clinical trial phase associated with the compound testing.","longName":"5038975v1.0:5040199v1.0","context":"OCG","contextVersion":"1","DataElementConcept":{"publicId":"5038975","version":"1","preferredName":"Compound Trial Phase","preferredDefinition":"A substance formed by chemical union of two or more elements or ingredients in definite proportion by weight._Clinical trials are broken into three or four phases: Phase I tests a new drug or treatment for safety in a small group; Phase II expands the study to a larger group of people; Phase III expands the study to an even larger group of people to measure whether the treatment actually benefits patients, and whether its benefits exceed its risks; and Phase IV takes place after the drug or treatment has been licensed and marketed.","longName":"2236710v1.0:2512776v1.0","context":"NCIP","contextVersion":"1","ObjectClass":{"publicId":"2236710","version":"1","preferredName":"Compound","preferredDefinition":"A substance formed by chemical union of two or more elements or ingredients in definite proportion by weight.","longName":"C43366","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Compound","conceptCode":"C43366","definition":"A substance formed by chemical union of two or more elements or ingredients in definite proportion by weight.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F9FC68BF-9D43-4A60-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-20","endDate":null,"createdBy":"UMLLOADER_MAGE","dateCreated":"2005-06-20","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2512776","version":"1","preferredName":"Trial Phase","preferredDefinition":"Clinical trials are broken into three or four phases: Phase I tests a new drug or treatment for safety in a small group; Phase II expands the study to a larger group of people; Phase III expands the study to an even larger group of people to measure whether the treatment actually benefits patients, and whether its benefits exceed its risks; and Phase IV takes place after the drug or treatment has been licensed and marketed.","longName":"C48281","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Trial Phase","conceptCode":"C48281","definition":"Clinical trials are broken into three or four phases: Phase I tests a new drug or treatment for safety in a small group; Phase II expands the study to a larger group of people; Phase III expands the study to an even larger group of people to measure whether the treatment actually benefits patients, and whether its benefits exceed its risks; and Phase IV takes place after the drug or treatment has been licensed and marketed.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"1B8A7A21-A0EA-2EAA-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-08-21","endDate":null,"createdBy":"UMLLOADER_AGNIS","dateCreated":"2006-08-21","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2435024","version":"1","preferredName":"Drug or Chemical","preferredDefinition":"A category of organic or inorganic substances, elements, and isotopes used in research or for the prevention, diagnosis, and/or treatment of disease states. Includes biologically active substances that are either synthetically manufactured or endogenous substances extracted and processed to be reintroduced into an organism. Chemicals and drugs also include hazardous substances, and naturally occurring or synthetically produced substances required to maintain life.","longName":"C1908","context":"NCIP","contextVersion":"1","origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"07431EBC-FB04-25D9-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-12-06","endDate":null,"createdBy":"CURTIST","dateCreated":"2005-12-06","modifiedBy":"SBR","dateModified":"2006-12-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"CTD2:Cancer Target Discovery and Development","workflowStatus":"RELEASED","registrationStatus":"Application","id":"232D6CEF-9C82-E734-E050-BB89AD434BDE","latestVersionIndicator":"Yes","beginDate":"2015-10-28","endDate":null,"createdBy":"COOPERM","dateCreated":"2015-10-28","modifiedBy":"COOPERM","dateModified":"2017-02-01","changeDescription":"Curated to support CTD2 activity per request by S.Jagu. mc 10/28/15","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"5040199","version":"1","preferredName":"Trial Phase Type","preferredDefinition":"Text term that represents the clinical trial phase associated with the compound testing.","longName":"5040199v1.0","context":"NCIP","contextVersion":"1","type":"Non-enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"10","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[],"ConceptualDomain":{"publicId":"2435024","version":"1","preferredName":"Drug or Chemical","preferredDefinition":"A category of organic or inorganic substances, elements, and isotopes used in research or for the prevention, diagnosis, and/or treatment of disease states. Includes biologically active substances that are either synthetically manufactured or endogenous substances extracted and processed to be reintroduced into an organism. Chemicals and drugs also include hazardous substances, and naturally occurring or synthetically produced substances required to maintain life.","longName":"C1908","context":"NCIP","contextVersion":"1","origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"07431EBC-FB04-25D9-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-12-06","endDate":null,"createdBy":"CURTIST","dateCreated":"2005-12-06","modifiedBy":"SBR","dateModified":"2006-12-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2234813","version":"1","preferredName":"Type","preferredDefinition":"Type; a subdivision of a particular kind of thing.","longName":"C25284","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"F970CDF6-F90E-21D3-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-14","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-06-14","modifiedBy":"SBR","dateModified":"2005-09-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"CTD2:Cancer Target Discovery and Development","workflowStatus":"RELEASED","registrationStatus":"Application","id":"2343D90C-F0A5-7371-E050-BB89AD431122","latestVersionIndicator":"Yes","beginDate":"2015-10-29","endDate":null,"createdBy":"COOPERM","dateCreated":"2015-10-29","modifiedBy":"COOPERM","dateModified":"2017-02-01","changeDescription":"Created for CTD^2 project per request by S.Jagu. mc 10/29/15","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"5646652","version":"1","longName":"CTD^2 (Cancer Target Discovery and Development","context":"OCG","ClassificationSchemeItems":[{"publicId":"5092552","version":"1","longName":"Approved CDEs","context":"OCG"}]}],"AlternateNames":[],"ReferenceDocuments":[{"name":"compound_clinical_status","type":"Preferred Question Text","description":"compound_clinical_status","url":null,"context":"OCG"}],"origin":"CTD2:Cancer Target Discovery and Development","workflowStatus":"RELEASED","registrationStatus":"Application","id":"23A9D571-FB85-939E-E050-BB89AD43758B","latestVersionIndicator":"Yes","beginDate":"2015-11-03","endDate":null,"createdBy":"COOPERM","dateCreated":"2015-11-03","modifiedBy":"COOPERM","dateModified":"2017-02-07","changeDescription":"Curated to support CTD2 activity per request by S.Jagu. mc 11/3/15 Changed from caBIG to CTD-2 for COOPERM by script 15-DEC-22 Moved from CTD-2 to OCG Context per request by S.Jagu. mc 2/1/17","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}